NO.1 恒瑞医药H股发售价定为每股44.05港元 5月21日,恒瑞医药(HK01276)公告称,公司已确定H股发行的最终价格为每股44.05港元,为原先预计发行价格的上限。恒瑞医药H股将于5月23日在香港联交所主板正式挂牌交易,其基石投资者包括新加坡政府投资公司(GIC)、景顺、瑞银全球资产管理集团、高瓴资本、博裕资本等知名机构。 点评:恒瑞医药此次H股发行的目的是进一步推动公司的全球化战略...
Source LinkNO.1 恒瑞医药H股发售价定为每股44.05港元 5月21日,恒瑞医药(HK01276)公告称,公司已确定H股发行的最终价格为每股44.05港元,为原先预计发行价格的上限。恒瑞医药H股将于5月23日在香港联交所主板正式挂牌交易,其基石投资者包括新加坡政府投资公司(GIC)、景顺、瑞银全球资产管理集团、高瓴资本、博裕资本等知名机构。 点评:恒瑞医药此次H股发行的目的是进一步推动公司的全球化战略...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.